Logo image of MYTE

MYT NETHERLANDS PARENT BV (MYTE) Stock Fundamental Analysis

USA - New York Stock Exchange - NYSE:MYTE - US55406W1036 - ADR

7.64 USD
-0.2 (-2.55%)
Last: 4/30/2025, 8:23:38 PM
Fundamental Rating

4

Taking everything into account, MYTE scores 4 out of 10 in our fundamental rating. MYTE was compared to 121 industry peers in the Specialty Retail industry. MYTE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. MYTE is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • In the past year MYTE was profitable.
  • In the past year MYTE has reported a negative cash flow from operations.
  • MYTE had negative earnings in 4 of the past 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: MYTE reported negative operating cash flow in multiple years.
MYTE Yearly Net Income VS EBIT VS OCF VS FCFMYTE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M -60M

1.2 Ratios

  • The Return On Assets of MYTE (-5.01%) is worse than 68.85% of its industry peers.
  • MYTE has a Return On Equity (-8.64%) which is in line with its industry peers.
  • MYTE has a worse Return On Invested Capital (0.05%) than 63.93% of its industry peers.
Industry RankSector Rank
ROA -5.01%
ROE -8.64%
ROIC 0.05%
ROA(3y)-2.35%
ROA(5y)-2.32%
ROE(3y)-3.64%
ROE(5y)-1.89%
ROIC(3y)N/A
ROIC(5y)N/A
MYTE Yearly ROA, ROE, ROICMYTE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 5 -5

1.3 Margins

  • The Operating Margin of MYTE (0.03%) is worse than 63.93% of its industry peers.
  • Looking at the Gross Margin, with a value of 47.04%, MYTE is in the better half of the industry, outperforming 72.13% of the companies in the same industry.
  • MYTE's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 0.03%
PM (TTM) N/A
GM 47.04%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.26%
GM growth 5Y-0.15%
MYTE Yearly Profit, Operating, Gross MarginsMYTE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 10 20 30 40 50

More info and screens

4

2. Health

2.1 Basic Checks

  • MYTE has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • MYTE has more shares outstanding than it did 1 year ago.
  • MYTE has less shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, MYTE has an improved debt to assets ratio.
MYTE Yearly Shares OutstandingMYTE Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
MYTE Yearly Total Debt VS Total AssetsMYTE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

  • MYTE has an Altman-Z score of 4.23. This indicates that MYTE is financially healthy and has little risk of bankruptcy at the moment.
  • With an excellent Altman-Z score value of 4.23, MYTE belongs to the best of the industry, outperforming 86.07% of the companies in the same industry.
  • MYTE has a Debt/Equity ratio of 0.19. This is a healthy value indicating a solid balance between debt and equity.
  • MYTE has a Debt to Equity ratio of 0.19. This is in the better half of the industry: MYTE outperforms 61.48% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Altman-Z 4.23
ROIC/WACC0.01
WACC7.41%
MYTE Yearly LT Debt VS Equity VS FCFMYTE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M

2.3 Liquidity

  • MYTE has a Current Ratio of 1.78. This is a normal value and indicates that MYTE is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 1.78, MYTE is in the better half of the industry, outperforming 76.23% of the companies in the same industry.
  • MYTE has a Quick Ratio of 1.78. This is a bad value and indicates that MYTE is not financially healthy enough and could expect problems in meeting its short term obligations.
  • With a Quick ratio value of 0.22, MYTE is not doing good in the industry: 85.25% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.78
Quick Ratio 0.22
MYTE Yearly Current Assets VS Current LiabilitesMYTE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

6

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 525.00% over the past year.
  • The Revenue has grown by 11.84% in the past year. This is quite good.
  • MYTE shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.27% yearly.
EPS 1Y (TTM)525%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%200%
Revenue 1Y (TTM)11.84%
Revenue growth 3Y11.16%
Revenue growth 5Y17.27%
Sales Q2Q%13.17%

3.2 Future

  • The Earnings Per Share is expected to grow by 54.63% on average over the next years. This is a very strong growth
  • MYTE is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.58% yearly.
EPS Next Y291%
EPS Next 2Y115.23%
EPS Next 3Y54.63%
EPS Next 5YN/A
Revenue Next Year9.06%
Revenue Next 2Y9.71%
Revenue Next 3Y9.58%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
MYTE Yearly Revenue VS EstimatesMYTE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2030 500M 1B 1.5B
MYTE Yearly EPS VS EstimatesMYTE Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0.1 0.2 0.3 0.4 0.5

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 27.29 indicates a quite expensive valuation of MYTE.
  • The rest of the industry has a similar Price/Earnings ratio as MYTE.
  • MYTE is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 27.32, which is the current average of the S&P500 Index.
  • With a Price/Forward Earnings ratio of 18.32, MYTE is valued on the expensive side.
  • Based on the Price/Forward Earnings ratio, MYTE is valued a bit cheaper than the industry average as 61.48% of the companies are valued more expensively.
  • When comparing the Price/Forward Earnings ratio of MYTE to the average of the S&P500 Index (24.30), we can say MYTE is valued slightly cheaper.
Industry RankSector Rank
PE 27.29
Fwd PE 18.32
MYTE Price Earnings VS Forward Price EarningsMYTE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

  • MYTE's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. MYTE is more expensive than 67.21% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 49.69
MYTE Per share dataMYTE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as MYTE's earnings are expected to grow with 54.63% in the coming years.
PEG (NY)0.09
PEG (5Y)N/A
EPS Next 2Y115.23%
EPS Next 3Y54.63%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for MYTE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MYT NETHERLANDS PARENT BV

NYSE:MYTE (4/30/2025, 8:23:38 PM)

7.64

-0.2 (-2.55%)

Chartmill FA Rating
GICS IndustryGroupConsumer Discretionary Distribution & Retail
GICS IndustrySpecialty Retail
Earnings (Last)02-11
Earnings (Next)05-14
Inst OwnersN/A
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap1.04B
Revenue(TTM)880.73M
Net Income(TTM)-35.85M
Analysts76.36
Price Target10.71 (40.18%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)151.51%
Min EPS beat(2)96.08%
Max EPS beat(2)206.95%
EPS beat(4)2
Avg EPS beat(4)50.27%
Min EPS beat(4)-50.98%
Max EPS beat(4)206.95%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.32%
Min Revenue beat(2)-3.03%
Max Revenue beat(2)0.39%
Revenue beat(4)1
Avg Revenue beat(4)-1.89%
Min Revenue beat(4)-4.24%
Max Revenue beat(4)0.39%
Revenue beat(8)3
Avg Revenue beat(8)-0.99%
Revenue beat(12)4
Avg Revenue beat(12)-1.89%
Revenue beat(16)7
Avg Revenue beat(16)-0.73%
PT rev (1m)0%
PT rev (3m)49.57%
EPS NQ rev (1m)-140.01%
EPS NQ rev (3m)-111.77%
EPS NY rev (1m)0%
EPS NY rev (3m)17.95%
Revenue NQ rev (1m)-0.36%
Revenue NQ rev (3m)-1.08%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.97%
Valuation
Industry RankSector Rank
PE 27.29
Fwd PE 18.32
P/S 1.05
P/FCF N/A
P/OCF N/A
P/B 2.23
P/tB 3.57
EV/EBITDA 49.69
EPS(TTM)0.28
EY3.66%
EPS(NY)0.42
Fwd EY5.46%
FCF(TTM)-0.14
FCFYN/A
OCF(TTM)-0.06
OCFYN/A
SpS7.27
BVpS3.42
TBVpS2.14
PEG (NY)0.09
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -5.01%
ROE -8.64%
ROCE 0.06%
ROIC 0.05%
ROICexc 0.05%
ROICexgc 0.07%
OM 0.03%
PM (TTM) N/A
GM 47.04%
FCFM N/A
ROA(3y)-2.35%
ROA(5y)-2.32%
ROE(3y)-3.64%
ROE(5y)-1.89%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.26%
GM growth 5Y-0.15%
F-Score3
Asset Turnover1.23
Health
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Debt/EBITDA 4.11
Cap/Depr 47.13%
Cap/Sales 1.02%
Interest Coverage 0.05
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.78
Quick Ratio 0.22
Altman-Z 4.23
F-Score3
WACC7.41%
ROIC/WACC0.01
Cap/Depr(3y)134.72%
Cap/Depr(5y)94.09%
Cap/Sales(3y)2.03%
Cap/Sales(5y)1.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)525%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%200%
EPS Next Y291%
EPS Next 2Y115.23%
EPS Next 3Y54.63%
EPS Next 5YN/A
Revenue 1Y (TTM)11.84%
Revenue growth 3Y11.16%
Revenue growth 5Y17.27%
Sales Q2Q%13.17%
Revenue Next Year9.06%
Revenue Next 2Y9.71%
Revenue Next 3Y9.58%
Revenue Next 5YN/A
EBIT growth 1Y101.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year188.35%
EBIT Next 3Y67.88%
EBIT Next 5YN/A
FCF growth 1Y18.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-407.95%
OCF growth 3YN/A
OCF growth 5Y33.41%

MYT NETHERLANDS PARENT BV / MYTE FAQ

What is the ChartMill fundamental rating of MYT NETHERLANDS PARENT BV (MYTE) stock?

ChartMill assigns a fundamental rating of 3 / 10 to MYTE.


What is the valuation status for MYTE stock?

ChartMill assigns a valuation rating of 3 / 10 to MYT NETHERLANDS PARENT BV (MYTE). This can be considered as Overvalued.


How profitable is MYT NETHERLANDS PARENT BV (MYTE) stock?

MYT NETHERLANDS PARENT BV (MYTE) has a profitability rating of 2 / 10.


What is the earnings growth outlook for MYT NETHERLANDS PARENT BV?

The Earnings per Share (EPS) of MYT NETHERLANDS PARENT BV (MYTE) is expected to grow by 291% in the next year.